Ensifentrine Suppliers & Bulk Manufacturers
Available Forms: Inhalation solution
Available Strengths: 3 mg per 2.5 mL
Reference Brands: Ohtuvayre (USA)
Category:
Respiratory Disorder
Ensifentrine is available in Inhalation solution
and strengths such as 3 mg per 2.5 mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ensifentrine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ensifentrine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Ensifentrine is an inhaled medication used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It is marketed under the brand name Ohtuvayre and represents a novel therapeutic approach by combining dual inhibition of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) in a single molecule. This dual mechanism allows ensifentrine to deliver both bronchodilator and anti-inflammatory effects, addressing key pathological features of COPD.
As a PDE3 inhibitor, ensifentrine helps relax airway smooth muscle, leading to bronchodilation and improved airflow. At the same time, its PDE4 inhibitory activity reduces airway inflammation, which contributes to symptom control and disease management. Ensifentrine is administered by inhalation, allowing targeted delivery directly to the lungs and minimizing systemic exposure.
Ensifentrine is indicated for long-term COPD management and is used to improve lung function and reduce respiratory symptoms. Its inhaled formulation makes it suitable for patients who require consistent, localized therapy. By combining bronchodilation and anti-inflammatory action in one treatment, ensifentrine offers a differentiated and effective option for personalized respiratory care in adult COPD patients.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing